Toll-like receptor agonists in cancer therapy

Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032- 18031)

(2017) W. H. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Attenuating Regulatory T Cell Induction by TLR Agonists through Inhibition of p38 MAPK Signaling in Dendritic Cells Enhances Their Efficacy as Vaccine Adjuvants and Cancer Immunotherapeutics

(2014) A. G. Jarnicki et al.   JOURNAL OF IMMUNOLOGY

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guérin (BCG) immunotherapy

(2010) A. M. JACKSON et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

(2009) Jonathan W. Friedberg et al.   BRITISH JOURNAL OF HAEMATOLOGY

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells

(2009) S. M. Makela et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

(2009) Sunhwa Kim et al.   NATURE

Vaccines for lymphomas: Idiotype vaccines and beyond

(2008) Roch Houot et al.   BLOOD REVIEWS

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

(2008) R.-M. Szeimies et al.   BRITISH JOURNAL OF DERMATOLOGY

NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model

(2008) Calin D. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma

(2008) Mark P. Purdue et al.   CARCINOGENESIS

CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans

(2008) W. N. Haining et al.   CLINICAL CANCER RESEARCH

Local Administration of PF-3512676 CpG-B Instigates Tumor-Specific CD8+ T-Cell Reactivity in Melanoma Patients

(2008) B. G. Molenkamp et al.   CLINICAL CANCER RESEARCH

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase–dependent mechanism

(2008) Olivier Manches et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Christian Manegold et al.   JOURNAL OF CLINICAL ONCOLOGY

Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells

(2008) Rachael A. Clark et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

(2008) Maja A. Hofmann et al.   JOURNAL OF IMMUNOTHERAPY

Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

(2008) Padmanee Sharma et al.   JOURNAL OF IMMUNOTHERAPY

A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY

A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05)

(2008) Nicholas Butowski et al.   JOURNAL OF NEURO-ONCOLOGY

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

(2008) H Conroy et al.   ONCOGENE

TLR signaling by tumor and immune cells: a double-edged sword

(2008) B Huang et al.   ONCOGENE

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

Polymorphisms in Toll-like receptor genes and risk of cancer

(2008) E M El-Omar et al.   ONCOGENE

The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine

(2008) C. Trumpfheller et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE